XR 5944

Drug Profile

XR 5944

Alternative Names: MLN 944; XR5944

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Xenova Group
  • Class Antineoplastics; Phenazines
  • Mechanism of Action DNA intercalators; DNA topoisomerase I inhibitors; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (IV)
  • 16 Mar 2005 Data from a media release have been added to the adverse events and Cancer therapeutic trials sections
  • 29 Nov 2004 Data presented at the British Cancer Research Meeting 2004 (BCRM-2004) have been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top